Venetoclax is a Bcl-2-specific inhibitor that was developed to avoid this toxicity and is used to treat hematological malignancies without thrombocytopenia.50 However, based on our results showing that venetoclax failed to exhibit apparent senolytic activity in senescent malignant meningioma cells, the targeting of Bcl-xL, not Bcl-2, is considered to be important for the induction of apoptosis in senescent meningioma cells. The gene discussed is BCL2; the disease is hematologic disorder.